Castleman′s病患者的CD4^+CD25^+调节性T细胞的研究

Study on Changes of CD4^+CD25^+ T Regulatory Cells in Peripheral Blood of Patients with Castleman's Disease

目的:探讨Castleman′s病患者外周血中CD4+CD25+调节性T细胞的变化及其与疾病的关系。方法:用流式细胞术对14例Castleman′s病患者及30例正常对照的外周血中CD4+CD25lowT细胞、CD4+CD25highT细胞、CD4+CD25highFOXP3+T细胞的比例进行检测。结果:局灶型Castleman′s病患者外周血中CD4+CD25lowT细胞、CD4+CD25highT细胞和CD4+CD25highFOXP3+T细胞比例在治疗前分别为(4.55±0.53)%、(0.73±0.09)%、(0.64±0.09)%;治疗后分别为(4.88±0.24)%、(1.0±0.10)%、(0.93±0.10)%,均低于正常对照组。治疗后这3种T细胞的比例较治疗前有显著升高(P<0.05)。多中心型患者外周血中这3种T细胞比例在治疗前分别为(9.43±0.81)%、(2.79±0.17)%、(2.46±0.09)%;治疗后(8.82±1.01)%、(2.71±0.10)%、(2.23±0.10)%,均高于正常对照组。结论:CD4+CD25+调节性T细胞在局灶型和多中心型Castleman′s病中的变化是不同的,这种不同的变化可能和这两型的临床表现和预后不同有关。

Objective：To investigate the changes of CD4^＋CD25^＋ T regulatory cells in peripheral blood of Castleman s disease（CD） and the correlationship with the disease.Methods：The proportion of CD4^＋CD25^low,CD4^＋CD25^high and CD4^＋CD25^high FOXP3＋ T cells in peripheral blood were measured in 14 patients with Castleman s disease before and after treatment and in 30 normal controls by flow cytometry.Results：The percentage of CD4^＋CD25^low,CD4^＋CD25^high and CD4^＋CD25^highFOXP3＋ T cells in localized CD were（4.55±0.53）%,（0.73±0.09）% and （0.64＋0.09） % respectively, before treatment ,significantly lower than the corresponding values in the controls,and was （4.88± 0.24）%, （1.03 ±0. 10）% and （0. 93±0. 10）% respectively,after treatment,demonstrating the increase of the 3 subtypes of T cells in peripheral blood （P〈0. 05）. The percentage of CD4^＋CD25^low,CD4^＋CD25^highand CD4^＋CD25^highFOXP3^＋T cells in multicentric CD were higher than those in the controls, and were （9. 43±0.81）%, （2. 79±0.17）% and （2. 46±0.09）% respectively, before treatment, and （8.82 ± 1.01） %, （3.71 ± 0. 10） % and （2.23 ± 0.10） % ,respectively,after treatment, significantly higher than the corresponding values in the controls. Conclusion：In localized type and rnulticentric type of CD, the changes of CD4^＋CD25^＋T regulatory cells are quite different, probably relating to the divergence of the two types in clinical manifestations and prognosis.